144 related articles for article (PubMed ID: 31939421)
1. Risk of serious adverse event and fatal adverse event with molecular target anticancer drugs in cancer patients: A meta-analysis.
Wang Z; Yang X; Wang J; Wang S; Mao X; Li M; Zhao Y; Wang W; Qi X; Wu T
J Cancer Res Ther; 2019; 15(7):1435-1449. PubMed ID: 31939421
[TBL] [Abstract][Full Text] [Related]
2. Treatment-related serious adverse events and fatal adverse events with regorafenib in cancer patients: a meta-analysis of phase 3 randomized controlled trials.
Cao M; Li F; Wang Y; Zhang J
Invest New Drugs; 2017 Dec; 35(6):834-838. PubMed ID: 28936569
[TBL] [Abstract][Full Text] [Related]
3. Risk of serious adverse events and fatal adverse events with sorafenib in patients with solid cancer: a meta-analysis of phase 3 randomized controlled trials†.
Gyawali B; Shimokata T; Ando M; Honda K; Ando Y
Ann Oncol; 2017 Feb; 28(2):246-253. PubMed ID: 27771613
[TBL] [Abstract][Full Text] [Related]
4. Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients : Nivolumab-related serious/fatal adverse events.
Zhao B; Zhao H; Zhao J
J Immunother Cancer; 2018 Oct; 6(1):101. PubMed ID: 30285872
[TBL] [Abstract][Full Text] [Related]
5. Fatal Adverse Events Associated with Pembrolizumab in Cancer Patients: A Meta-Analysis.
Sher AF; Golshani GM; Wu S
Cancer Invest; 2020 Feb; 38(2):130-138. PubMed ID: 31985314
[No Abstract] [Full Text] [Related]
6. Risk of treatment-related mortality with sorafenib in patients with cancer.
Zhang XJ; Zhang TY; Yu FF; Wei X; Li YS; Xu F; Wei LX; He J
Asian Pac J Cancer Prev; 2014 Jan; 14(11):6681-6. PubMed ID: 24377588
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of incidence and risk of severe adverse events and fatal adverse events with crizotinib monotherapy in patients with
Zhu Q; Hu H; Jiang F; Guo CY; Yang XW; Liu X; Kuang YK
Oncotarget; 2017 Sep; 8(43):75372-75380. PubMed ID: 29088872
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis on the risk of fatal adverse events by bevacizumab, cetuximab, and panitumumab in 31 randomized trials including 25,000 patients with colorectal carcinoma.
Chen J; Wang J; Ni T; He H; Zheng Q
Medicine (Baltimore); 2020 Jun; 99(25):e19908. PubMed ID: 32569154
[TBL] [Abstract][Full Text] [Related]
9. Risk of treatment-related mortality in cancer patients treated with ipilimumab: A systematic review and meta-analysis.
Zhang S; Liang F; Li W; Wang Q
Eur J Cancer; 2017 Sep; 83():71-79. PubMed ID: 28719841
[TBL] [Abstract][Full Text] [Related]
10. Treatment-related mortality with aflibercept in cancer patients: a meta-analysis.
Qi WX; Tang LN; Shen Z; Yao Y
Eur J Clin Pharmacol; 2014 Apr; 70(4):461-7. PubMed ID: 24390630
[TBL] [Abstract][Full Text] [Related]
11. Incidence and risk of treatment-related mortality in cancer patients treated with EGFR-TKIs: a meta-analysis of 22 phase III randomized controlled trials.
Qi WX; Tang LN; He AN; Yao Y; Shen Z
Respir Med; 2013 Aug; 107(8):1280-3. PubMed ID: 23810268
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: a systematic review and meta-analysis of randomized controlled trials.
Funakoshi T; Latif A; Galsky MD
Cancer Treat Rev; 2014 Jun; 40(5):636-47. PubMed ID: 24629273
[TBL] [Abstract][Full Text] [Related]
13. Incidence and risk of treatment-related mortality with anti-epidermal growth factor receptor monoclonal antibody in cancer patients: a meta-analysis of 21 randomized controlled trials.
Li X; Shan BE; Wang J; Xing LP; Guo XJ; Zhang YH; Shi PH; Wang ZY
PLoS One; 2013; 8(11):e81897. PubMed ID: 24312376
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with breast cancer treated with HER2 blockade.
Wu J; Qiu K; Zhu J; Li J; Lin Y; He Z; Li G
Breast; 2015 Dec; 24(6):699-704. PubMed ID: 26376461
[TBL] [Abstract][Full Text] [Related]
15. Incidence and risk of treatment-related mortality with mTOR inhibitors everolimus and temsirolimus in cancer patients: a meta-analysis.
Qi WX; Huang YJ; Yao Y; Shen Z; Min DL
PLoS One; 2013; 8(6):e65166. PubMed ID: 23785409
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis of randomized controlled trials for the incidence and risk of fatal adverse events in cancer patients treated with ipilimumab.
Zhu J; Wu J; Li G; Li J; Lin Y; He Z; Su C; Zhao W; Wu Q; Chen Z; Qiu K
Expert Opin Drug Saf; 2017 Apr; 16(4):423-428. PubMed ID: 28276859
[TBL] [Abstract][Full Text] [Related]
17. Risk of incremental toxicities and associated costs of new anticancer drugs: a meta-analysis.
Niraula S; Amir E; Vera-Badillo F; Seruga B; Ocana A; Tannock IF
J Clin Oncol; 2014 Nov; 32(32):3634-42. PubMed ID: 25267757
[TBL] [Abstract][Full Text] [Related]
18. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary.
Brahmer JR; Lacchetti C; Thompson JA
J Oncol Pract; 2018 Apr; 14(4):247-249. PubMed ID: 29517954
[No Abstract] [Full Text] [Related]
19. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.
Ranpura V; Hapani S; Wu S
JAMA; 2011 Feb; 305(5):487-94. PubMed ID: 21285426
[TBL] [Abstract][Full Text] [Related]
20. Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis.
Dai J; Belum VR; Wu S; Sibaud V; Lacouture ME
J Am Acad Dermatol; 2017 Nov; 77(5):902-910.e2. PubMed ID: 28918974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
